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We conducted a nationwide hospital-based prospec-
tive study in Germany of infl uenza A(H1N1)pdm09 cases 
among children <15 years of age admitted to pediatric inten-
sive care units and related deaths during the 2009–10 pan-
demic and the 2010–11 postpandemic infl uenza seasons. 
We identifi ed 156 eligible patients: 112 in 2009–10 and 44 
in 2010–11. Although a shift to younger patients occurred in 
2010–11 (median age 3.2 vs. 5.3 years), infants <1 year of 
age remained the most affected. Underlying immunosup-
pression was a risk factor for hospital-acquired infections 
(p = 0.013), which accounted for 14% of cases. Myocarditis 
was predictive of death (p = 0.006). Of the 156 case-pa-
tients, 17% died; the difference between seasons was not 
signifi cant (p = 0.473). Our fi ndings stress the challenge of 
preventing severe postpandemic infl uenza infection in chil-
dren and the need to prevent nosocomial transmission of 
infl uenza virus, especially in immunosuppressed children.
In Germany during the infl uenza A(H1N1)pdm09 pan-demic, there were ≈1,070,000 infl uenza-related medical 
consultations and ≈1,800 hospitalizations for children 0–14 
years of age during  October 12, 2009–January 15, 2010, 
as determined using data provided by the German syn-
dromic surveillance system for acute respiratory infections 
(1). Moreover, 29 laboratory-confi rmed A(H1N1)pdm09 
infection–related deaths in children were notifi ed through 
the mandatory German surveillance system for infectious 
diseases (2). The highest number of notifi ed hospitaliza-
tions and deaths were among children 10–14 years of age 
(3,4). In a nationwide hospital-based observational study 
investigating severely ill children who had been admit-
ted to pediatric intensive care units (PICUs) or had died 
with laboratory-confi rmed A(H1N1)pdm09, we reported 
a high proportion (75%) of case-patients with underlying 
risk factors, of which neurodevelopmental disorders were 
most prevalent (5). In addition, we found that in 10% of the 
cases, children had acquired their infection while hospital-
ized and that few had been vaccinated, revealing a need for 
improving preventive measures to reduce severe disease 
and adverse outcomes (5).
On August 10, 2010, the general director of the 
World Health Organization declared the world was no 
longer in phase 6 of infl uenza pandemic alert; we were 
moving into the postpandemic phase (6). Experience from 
past pandemics suggested that the pandemic virus would 
gradually take on the behavior of a seasonal infl uenza vi-
rus and circulate for several years. However, in view of 
the potential for transformation of the virus into a more 
virulent form (7), as suggested by higher rates of mortal-
ity during second pandemic waves in Copenhagen (1918), 
the United States (1957), and Eurasia (1968–1970) (8,9), 
the World Health Organization acknowledged the unpre-
dictability of pandemic viruses; recommended continued 
vigilance; and issued advice on surveillance, vaccination, 
and prompt clinical management of cases during the post-
pandemic phase (6).
Little is known about the severity of A(H1N1)pdm09 
in children during the fi rst postpandemic season (10). To 
obtain information on critically ill A(H1N1)pdm09-infect-
ed children and to compare risk factors and disease course, 
outcome, and severity for patients during the pandemic 
and fi rst postpandemic season, we prospectively and con-
tinuously performed a nationwide study in Germany during 
August 3, 2009–July 29, 2011.
Methods
Study Design
We conducted a nationwide prospective observational 
study in Germany by using the German Survey Center for 
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Rare Pediatric Diseases (ESPED; an established children’s 
hospitals network comprising all 375 pediatric hospitals in 
Germany) to identify children <15 years of age admitted 
to PICUs with confi rmed A(H1N1)pdm09 infection and 
related deaths. Cases and related deaths during August 3, 
2009–July 29, 2011 were reported by using a standardized 
form. In pandemic season 2009–10 (August 3, 2009–Au-
gust 9, 2010), the case defi nition included only A(H1N1)
pdm09 infection; in postpandemic season 2010–11 (Au-
gust 10, 2010–July 29, 2011), the case defi nition included 
all infl uenza virus infections.
Data Collection
On notifi cation by treating physicians of patients 
with A(H1N1)pdm09 infection, the ESPED study center 
distributed and subsequently collected a structured ques-
tionnaire, which had been adapted by the authors from an 
earlier study on seasonal infl uenza (11). Of 284 distributed 
questionnaires requested by 186 hospitals, 95% (271/284) 
were returned to the study center (Figure 1). After exclud-
ing 3 questionnaires that had been notifi ed twice and 101 
questionnaires for patients who did not meet the case defi -
nition, 62% (167/271) of the questionnaires from 83 hospi-
tals remained. Reasons for not meeting the case defi nition 
included patient age >15 years and patient not admitted to 
PICU. In accordance with the case defi nition, only cases 
of A(H1N1)pdm09 infection were reported during the pan-
demic season (2009–10), and 9 cases of infl uenza A (not 
further subtyped) and 2 cases of infl uenza B infection were 
reported in the postpandemic season (2010–11). Therefore, 
further analyses were restricted to A(H1N1)pdm09 cases.
The structured questionnaire covered anonymous pa-
tient information and information regarding the hospital 
stay, clinical signs and symptoms, clinical and laboratory 
fi ndings, specifi c treatments, status of infl uenza vaccina-
tion, disease complications, and underlying chronic medical 
conditions (chronic respiratory diseases; cardiac diseases; 
immunodefi ciency; and neurodevelopmental disorders, in-
cluding developmental delay, cerebral palsy, epilepsy, and 
other cognitive disorders). Answer categories were prede-
termined, but free space was designated for respondents to 
provide information about other diagnoses and coexisting 
illnesses/medical conditions. Hospital-acquired infection 
was defi ned by a date of symptom onset being >2 days after 
the date of hospital admission; 2 days corresponds with the 
median incubation time for A(H1N1)pdm09 according to 
Cao et al. (12). Data were double entered by using EpiData 
3.1 software (www.epidata.dk/) in an electronic database.
Data Analysis
Reported values are those for children with available 
information. Descriptive statistics comprised the calcula-
tion of median and interquartile ranges (IQRs) for con-
tinuous variables and absolute numbers and proportions 
(together with 95% binomial exact CIs, when appropri-
ate) for categorical variables. Comparative analyses were 
based on the Wilcoxon rank-sum test for continuous vari-
ables and Fisher exact test for categorical variables. Odds 
ratios (ORs) and 95% CIs were calculated. Multivariable 
analysis was performed by using a logistic regression with 
a stepwise approach to compare cases of hospital-acquired 
infection with cases of community-acquired infection and 
survivors with nonsurvivors in PICUs. In doing so, risk 
factors with a p value <0.2 were considered for multivari-
able analysis, with the exception of age, sex, and season, 
which were included in all models. Reported p values are 
2-sided, and p<0.05 was considered signifi cant. Statistical 
analyses were performed by using Stata 11.0 (StataCorp 
LP, College Station, TX, USA).
Data Protection and Ethics Clearance
Adherence to national data protection laws was ap-
proved by the Federal Commissioner for Data Protection 
and Freedom of Information of Germany. Ethical approval 
was granted by the Ethics Committee, Charité-Univer-
sitätsmedizin, Berlin, Germany.
Results
Comparison of 2009–10 and 2010–11 Seasons
We identifi ed 156 critically ill children with con-
fi rmed A(H1N1)pdm09 infection: 112 in 2009–10 and 44 
in 2010–11 (Figure 1). Dates of symptom onset ranged 
from September 21, 2009, to March 20, 2010, for 2009–10 
1756 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 11, November 2012
Figure 1. Overview of study participation and participant groups 
among severe pediatric cases with A(H1N1)pdm09, Germany, 
2009–2011. PCIU, pediatric intensive care unit.
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and from December 20, 2010, to February 22, 2011, for 
2010–11 (Figure 2). Cases were reported from 15 of the 
16 federal states in Germany during 2009–10 and from 10 
during 2010–11.
The proportion of boys among case-patients was 
higher in 2009–10 than 2010–11 (59% vs. 37%, p = 0.02) 
(Table 1). The median age of case-patients was 5.3 and 3.2 
years in 2009–10 and 2010–11, respectively, and differed 
statistically (p = 0.007) between the 2 seasons. The age dis-
tribution in 2010–11 compared with that in 2009–10 was 
characterized by a markedly higher proportion of children 
< 2 years of age and a lower proportion of children 10–14 
years of age (Figure 3). In both seasons, infants <1 year of 
age represented the age group with the highest number of 
cases (Figure 4).
Of the 146 children with available information, 114 
(78%) had >1 chronic underlying medical condition; the 
difference between seasons for these conditions was not 
statistically signifi cant (Table 1). In both seasons, neuro-
developmental disorders were the most prevalent under-
lying medical condition. Of the 156 critically ill case-
patients, 130 were >6 months age and thus eligible for 
vaccination against A(H1N1)pdm09 virus; however, for 
children with available information on vaccination status, 
only 5 (7%) of 67 vaccine-eligible case-patients had been 
vaccinated in the 2009–10 season, and none had been vac-
cinated in the 2010–11 season. Of the 69 total children 
in both seasons with underlying chronic medical condi-
tions, 64 (93%) had not been vaccinated against A(H1N1)
pdm09 virus.
More cases of sepsis were reported during the postpan-
demic season than during the pandemic season (21% vs. 
8%; p = 0.048) (Table 1). Treatment with oseltamivir was 
used equally (in ≈62% of children) during both seasons. 
The time to oseltamivir administration after symptom onset 
(median 4 days) was similar throughout both seasons. The 
use of catecholamine and mechanical ventilation was more 
frequent in 2010–11 than in 2009–10, but the difference 
was not statistically different.
Hospital-acquired Infections
Hospital-acquired infections accounted for 11% (11 
of 101) of the cases in 2009–10 and for 23% (8/35) in 
2010–11 (p = 0.0931) (Table 1). Of the total study cohort, 
14% (19/136) of the patients (9 in a general ward and 10 
in a PICU) most likely had hospital-acquired infection. For 
these case-patients, the median time from hospital admis-
sion to symptom onset was 29 days (IQR 12–73 days). The 
median age for patients with hospital-acquired infection 
was 1.1 years, and 56% (10/18) were boys (difference not 
statistically signifi cant between seasons).
The overall case-fatality ratios were 26% (5/19) among 
patients with hospital-acquired infection and 20% (23/117) 
among those with community-acquired infection (p = 
0.543). Compared with patients with community-acquired 
infection, those with hospital-acquired infection had more 
complications, including acute respiratory distress syn-
drome (ARDS) (OR 2.7, p = 0.054) and sepsis (OR 3.1, p = 
0.064), but the differences were not statistically signifi cant 
(Table 2). In the multivariable model, immunodefi ciency 
(OR 5.9, 95% CI 1.5–23.9; p = 0.013) and mechanical ven-
tilation (OR 8.9, 95% CI 1.1–74.7; p = 0.043) were sig-
nifi cantly associated with hospital-acquired infection after 
adjusting for age, sex, and season.
Case Fatalities Ratios
The case fatality ratio in PICUs did not differ between 
seasons: 15% (16/106) and 21% (9/44) of PICU case-
patients died in 2009–10 and 2010–11, respectively (p = 
0.473) (Table 1). For the 2 seasons, 25 of 150 PICU case-
patients died, corresponding to a case-fatality ratio of 17% 
(95% CI 11%–24%). On hospital discharge, 26% (27/104) 
of the survivors were reported to have possible sequelae or 
worsening of a pre-existing medical condition.
No statistical differences were found between survi-
vors and nonsurvivors in underlying chronic medical con-
ditions and vaccination status. ARDS (OR 3.2, 95% CI 
1.1–9.2, p = 0.029), myocarditis (OR 30.9, 95% CI 2.6–
360.7,; p = 0.006), and mechanical ventilation (OR 18.3; 
95% CI 1.3–251.6, p = 0.030) were independently associ-
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Figure 2. Distribution of 
136 critically ill children 
with confi rmed A(H1N1)
pdm09, by date of disease 
onset, September 21, 2009–
February 22, 2011, Germany. 
Only cases with available 
date of symptom onset are 
represented.
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ated with a fatal outcome in the multivariable model after 
adjusting for age, sex, and season (Table 3).
Compared with survivors, nonsurvivors more fre-
quently required mechanical ventilation (p = 0.001) and 
treatment with catecholamine (p = 0.002); no differences 
were found in oseltamivir administration (65% vs. 62%, 
p = 0.8185). Time from symptom onset to oseltamivir 
uptake did not differ between survivors (median 4 days, 
IQR 1–6 days) and nonsurvivors (median 4 days, IQR 2–8 
days).
Discussion
During the fi rst postpandemic season, fewer cases of 
A(H1N1) pdm09 infection were reported, but the severity 
and outcome of cases did not differ between the pandemic 
and postpandemic seasons. We further analyzed data from 
the 2 seasons as 2 outbreak waves of 1 virus and identifi ed a 
high number of hospital-acquired infections and ARDS and 
myocarditis as 2 predictors for a fatal outcome.
Compared with the 2009–10 pandemic season, the 
2010–11 postpandemic season started later in the winter 
and had less than half the number of cases. High disease 
awareness during the pandemic season may have enhanced 
testing and reporting during 2009–10; thus the reduced 
case number for 2010–11 should be interpreted with cau-
tion. However in the United States, where reporting of 
infl uenza-related deaths in children is mandatory, a similar 
decline in the number of fatal A(H1N1)pdm09-associated 
cases was noted between the 2009–10 and 2010–11 infl u-
enza seasons (282 and 71 deaths among children, respec-
tively) (13). Before the 2009–10 pandemic and similar to 
the postpandemic season, an average of 82 (range 46–153) 
children in the United States died each year from seasonal 
infl uenza–related illnesses (14). However, in the postpan-
demic 2010–11 season, different proportions of all circulat-
ing infl uenza subtypes might have led to different numbers 
of persons exposed to A(H1N1)pdm09, which makes com-
parisons between seasons and across countries diffi cult.
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Figure 3. Proportion of critically ill children with A(H1N1)pdm09 by 
age group and season, Germany.
Table 1. Comparison of severe cases of influenza A(H1N1)pdm09 virus infection in children during the pandemic and the first 
postpandemic seasons, Germany, 2009–2011* 
Variable No. patients/no. total (%)
Influenza season 
p value 2009–10 2010–11 
Male sex 81/154 (53) 65/111 (59) 16/43 (37) 0.020 
Median age, y (IQR) 4.2 (1.2–9.2) 5.3 (1.7–10.1) 3.2 (0.5–6.5) 0.007 
Hospital-acquired infection 19/136 (14) 11/101 (11) 8/35 (23) 0.093 
Clinical diagnosis     
 Pneumonia 108/156 (69) 79/112 (71) 29/44 (66) 0.569 
 Secondary pneumonia 30/156 (19) 22/112 (20) 8/44 (18) 1.000 
 Encephalopathy 11/156 (7) 7/112 (6) 4/44 (9) 0.506 
 ARDS 43/156 (28) 29/112 (26) 14/44 (32) 0.551 
 Sepsis 18/156 (12) 9/112 (8) 9/44 (21) 0.048 
 Myocarditis 8/156 (5) 4/112 (4) 4/44 (9) 0.223 
 Febrile seizure 7/156 (5) 3/112 (3) 4/44 (9) 0.099 
Underlying chronic medical conditions     
 Any 114/146 (78) 82/107 (77) 32/39 (82) 0.652 
 Neurodevelopmental disorders 84/151 (56) 61/110 (56) 23/41 (56) 1.000 
 Respiratory disease 44/141 (31) 35/104 (34) 9/37 (24) 0.409 
 Immunodeficiency 17/137 (12) 15/97 (16) 2/40 (5) 0.152 
 Cardiac disease 20/143 (14) 12/102 (12) 8/41 (20) 0.286 
Treatment     
 Oseltamivir 90/145 (62) 65/105 (62) 25/40 (63) 1.000 
 Catecholamine 52/138 (38) 35/101 (35) 17/37 (46) 0.240 
 Mechanical ventilation 98/145 (68) 68/107 (64) 30/38 (79) 0.107 
 Vaccination† 5/88 (6) 5/67 (8) 0/21 (0) 0.332 
Outcome     
 All deaths 31/156 (20) 22/112 (20) 9/44 (21) 1.000 
 Death in PICU 25/150 (17) 16/106 (15) 9/44 (21) 0.473 
*Values are no. positive/no. with available information (%), except as indicated. Pandemic season, 2009–10; postpandemic season, 2010–11; IQR, 
interquartile range; ARDS, acute respiratory distress syndrome; PICU, pediatric intensive care unit.  
†Influenza A(H1N1)pdm09 vaccination of patients >6 mo of age. 
 Infl uenza A(H1N1)pdm09 Infection in Children
For the 2010–11 season, we assumed a more limited 
number of susceptible persons because exposure to infl u-
enza virus during the pandemic might have provided immu-
nologic protection (15–17). This hypothesis is supported by 
our results showing a shift toward infection in younger age 
groups in 2010–11. A similar fi nding was reported in a pro-
spective study of children with A(H1N1)pdm09 infection in 
a Spanish hospital (median age 7.0 and 0.8 years in 2009–10 
and 2010–11, respectively) (10). During both seasons, chil-
dren <1 year of age were more affected than those in other 
age groups, and the numbers infected in the 2 seasons were 
similar; therefore, infl uenza infection in this immunologi-
cally naive age group might always refl ect a pandemic-like 
situation. It remains unexplained why more boys in 2009–10 
(59%, 65/111) than in 2010–11 (37%, 16/43) had serious 
A(H1N1)pdm09 infection, although it has been suggested 
that the difference in age distribution between the 2 seasons 
could have infl uenced the sex distribution (18).
Our results show that case-fatality ratios for the 2 sea-
sons were similar. In Greece (19) and New-Zealand (20), 
according to the respective national surveillance systems in 
intensive care unit settings, case-fatality ratios among all 
age groups were also similar for the 2 seasons. This result 
is reassuring, in view of concerns of a possible transfor-
mation of the strain into a more severe form (7), and is in 
agreement with the antigenic and genetic homogeneity of 
the virus since its emergence (21).
In both seasons, we identifi ed a large number of prob-
able hospital-acquired A(H1N1)pdm09 infections. Immu-
nodefi ciency, most often reported as acute lymphoblastic 
leukemia, was associated with hospital-acquired infection, 
and this underlying chronic medical condition, has also 
been identifi ed as a risk factor for community-acquired 
A(H1N1)pdm09 (22,23). Findings from a retrospective 
hospital-based study investigating the prevalence of respi-
ratory virus infections among children with cancer or HIV 
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Figure 4. Age distribution of the 156 critically ill children with 
confi rmed A(H1N1)pdm09, by season, Germany.
Table 2. Comparison of hospital- and community-acquired cases of severe influenza A(H1N1)pdm09 infection in children during the








Univariable analysis  Multivariable analysis 
OR (95% CI) p value OR (95% CI) p value
Male sex 72/134 (54) 10/18 (56) 62/116 (54) 1.1 (0.4–3.4) 1.000  1.4 (0.4–4.5) 0.622 
Median age, years (IQR) 4.3 (1.0–9.2) 1.1 (0.3–10.1) 4.8 (1.6–11.9) NA 0.168  1.0 (0.8–1.1) 0.583 
2010–11 season 35/136 (26) 8/19 (42) 27/117 (23) 2.4 (0.8–7.4) 0.093  1.5 (0.4–5.7) 0.517 
Clinical diagnosis         
 Pneumonia 96/136 (71) 15/19 (79) 81/117 (69) 1.7 (0.5–7.4) 0.588  NA NA 
 Secondary pneumonia 27/136 (20) 4/19 (21) 23/117 (20) 1.1 (0.2–3.8) 1.000  NA NA 
 Encephalopathy 9/136 (7) 0/19 (0) 9/117 (8) 0.0 (0.0–2.5) 0.360  NA NA 
 ARDS 38/136 (28) 9/19 (47) 29/117 (25) 2.7 (0.9–8.2) 0.054  NA NA 
 Sepsis 17/136 (13) 5/19 (26) 12/117 (10) 3.1 (0.7–11.4) 0.064  NA NA 
 Myocarditis 8/136 (6) 0/19 (0) 8/117 (7) 0.0 (0.0–2.9) 0.600  NA NA 
 Febrile seizure 6/136 (4) 0/19 (0) 6/117 (5) 0.0 (0.0–3.9) 0.595  NA NA 
Underlying chronic medical conditions        
 Any 101/129 (78) 19/19 (100) 82/110 (75) NA (1.7–NA) 0.013  NA NA 
 Neurodevelopmental  
 disorders 
75/133 (56) 13/19 (68) 62/114 (54) 1.8 (0.6–6.2) 0.321  NA NA 
 Respiratory disease 17/126 (14) 3/18 (17) 14/108 (13) 1.3 (0.2–5.7) 0.710  NA NA 
 Immunodeficiency 15/121 (12) 5/17 (29) 10/104 (10) 3.9 (0.9–15.2) 0.037  5.9 (1.5–23.9) 0.013 
 Cardiac disease 17/126 (14) 3/18 (17) 14/108 (13) 1.3 (0.2–5.7) 0.710  NA NA 
Treatment         
 Oseltamivir 80/128 (63) 13/18 (72) 67/110 (61) 1.7 (0.5–6.4) 0.4378  NA NA 
 Catecholamine 47/124 (38) 11/16 (69) 36/108 (33) 4.4 (1.3–17.2) 0.011  NA NA 
 Mechanical ventilation 85/129 (66) 17/18 (94) 68/111 (61) 10.8 (1.6–459.4) 0.006  8.9 (1.1–74.7) 0.043 
 Vaccination† 5/80 (6) 0/10 (0) 5/70 (7) 0.0 (0.0–5.5) 1.000  NA NA 
Outcome         
 All death 28/136 (21) 5/19 (26) 23/117 (20) 1.5 (0.4–4.9) 0.543  NA NA 
 Death in PICU 22/130 (17) 4/18 (22) 18/112 (16) 1.5 (0.3–5.5) 0.507  NA NA 
*Values are no. positive/no. with available information (%), except as indicated. Pandemic season, 2009–10; postpandemic season, 2010–11; OR, odds 
ratio; IQR, interquartile range; NA, not applicable; ARDS, acute respiratory distress syndrome; PICU, pediatric intensive care unit. 
†Influenza A(H1N1)pdm09 vaccination of patients >6 mo of age. 
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infection reported that 40% of the respiratory infections 
were acquired during the hospital stay, and infl uenza A 
virus was the second most prevalent respiratory infection 
(24). In our study, patients with hospital-acquired infection 
had more complications, including ARDS and sepsis, than 
patients with community-acquired infections. However, 
a signifi cant association between hospital-acquired infec-
tion and death was not found, possibly because of the small 
number of cases, as found by Spaeder et al. (25) in a retro-
spective cohort study in PICU setting. In this study, hospi-
tal acquisition of viral respiratory infection was shown to 
be associated with an increased risk for death, even after 
adjusting for chronic medical conditions that predispose to 
an increased risk for complications from viral illness. Our 
fi ndings emphasize the need for isolation of and preventive 
measures for children with immunodefi ciency, as report-
ed (26). Preventive measures should include the vaccina-
tion of health care workers. Indeed, a survey in Germany 
showed that only 35% (n = 3,900) of the health care work-
ers in a university hospital setting were vaccinated during 
the 2010–11 infl uenza season (27). Studies in earlier sea-
sons showed even lower infl uenza vaccination rates among 
health care workers (28).
We identifi ed 25 A(H1N1)pdm09-associated deaths 
among children admitted to PICUs during the pandemic 
and postpandemic seasons. ARDS was the most prevalent 
complication among case-patients who died (60% of cases) 
and was highly associated with death. Myocarditis was also 
highly associated with death in children; this fi nding sup-
ports those among adults (29,30) and other fi ndings among 
A(H1N1)pdm09-infected children (31).
During both seasons, 62% of the children received 
oseltamivir treatment. This proportion is lower than de-
scribed in other studies in PICU settings, e.g., 81% in 
an inception-cohort study in Australia and New Zealand 
(32), 88% in a US cohort (31), 96% in a retrospective ob-
servational multicenter study in Turkey (33), and 100% 
of children in a retrospective Dutch cohort (34). Obser-
vational and random clinical trials have shown the poten-
tial of oseltamivir to reduce the length of hospitalization 
when started <24 hours of illness onset (35,36). The In-
fectious Diseases Society of America recommends that 
any person with confi rmed or suspected infl uenza who 
requires hospitalization receive infl uenza antiviral thera-
py, even if the patient enters care >48 hours after illness 
onset (37). The German Society for Pediatric Infectious 
Diseases recommends that immunocompetent children 
without underlying chronic medical conditions should not 
receive infl uenza antiviral therapy >48 hours after onset 
of infl uenza symptoms (38). Most A(H1N1)pdm09 virus 
isolates tested worldwide remain sensitive to oseltamivir; 
thus, strategies to optimize the use of oseltamivir should 
be considered, and additional evidence should be col-
lected with respect to reduction of nosocomial spread of 
A(H1N1)pdm09 virus and to potential benefi ts from late 
treatment in severely ill children.
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Table 3. Comparison of severe cases of influenza A(H1N1)pdm09 infection among children in PICUs during the pandemic and first 
postpandemic influenza seasons, Germany, 2009–2011* 
Variable
No. patients/ 
total (%) Nonsurvivors Survivors 
Univariable analysis Multivariable analysis 
OR (95% CI) p value OR (95% CI) p value
Male sex 81/148 (55) 15/25 (60) 66/123 (54) 1.3 (0.5–3.5) 0.661 2.5 (0.8–7.4) 0.098 
Median age, years (IQR) 4.2(1.0–8-6) 5.7 (1.6–9.8) 4.1 (1–7.8) NA 0.091 1.1 (1.0–1.2) 0.232 
2010–11 season 44/150 (29) 9/25 (36) 35/125 (28) 1.4 (0.5–3.9) 0.4728 1.6 (0.5–5.1) 0.435 
Hospital-acquired infection 18/130 (14) 4/22 (18) 14/108 (13) 1.5 (0.3–5.5) 0.507 NA NA 
Clinical diagnosis        
 Pneumonia 103/150 (69) 13/25 (52) 90/125 (72) 0.4 (0.2–1.1) 0.060 NA NA 
 Secondary pneumonia 30/150 (20) 8/25 (32) 22/125 (18) 2.2 (0.7–6.2) 0.108 NA NA 
 Encephalopathy 11/150 (7) 1/25 (4) 10/125 (8) 0.5 (0.01–3.7) 0.692 NA NA 
 ARDS 43/150 (29) 15/25 (60) 28/125 (22) 5.2 (1.9–14.3) <0.001 3.2 (1.1–9.2) 0.029 
 Sepsis 17/150 (11) 6/25 (24) 11/125 (9) 3.3 (0.9–11.0) 0.040 NA NA 
 Myocarditis 8/150 (5) 4/25 (16) 4/125 (3) 5.8 (1.0–32.9) 0.027 30.9 (2.6–360.7) 0.006 
 Febrile seizure 7/150 (5) 0/25 (0) 7/125 (6) 0.0 (0.01–2.7) 0.601 NA NA 
Underlying chronic medical condition       
 Any 108/140 (77) 19/23 (83) 89/117 (76) 1.5 (0.4–6.5) 0.596 NA NA 
 Neurodevelopmental  
 disorder 
78/145 (54) 16/24 (67) 62/121 (51) 1.9 (0.7–5.5) 0.186 NA NA 
 Respiratory disease 42/135 (31) 8/22 (36) 34/113 (30) 1.3 (0.4–3.8) 0.617 NA NA 
 Immunodeficiency 16/131 (12) 1/21 (5) 15/110 (14) 0.3 (0.0–2.3) 0.467 NA NA 
 Cardiac disease 20/137 (15) 4/23 (17) 16/114 (14) 1.3 (0.3–4.6) 0.746 NA NA 
Treatment        
 Oseltamivir 87/139 (63) 15/23 (65) 72/116 (62) 1.1 (0.4–3.4) 0.8185 NA NA 
 Catecholamine 52/133 (39) 16/23 (70) 36/110 (33) 4.7 (1.6–14.6) 0.002 NA NA 
 Mechanical ventilation 98/140 (70) 23/24 (96) 75/116 (65) 12.6 (1.9–530.3) 0.001 18.3 (1.3–251.6) 0.030 
 Vaccination† 5/82 (6) 0/14 (0) 5/68 (7) 0.0 (0.0–3.7) 0.582 NA NA 
*Values are no. positive/no. with available information (%), except as indicated. PICUs, pediatric intensive care units; pandemic season, 2009–10; 
postpandemic season, 2010–11; OR, odds ratio; IQR, interquartile range; NA, not applicable; ARDS, acute respiratory distress syndrome.
†Influenza A(H1N1)pdm09 vaccination of patients >6 mo of age. 
 Infl uenza A(H1N1)pdm09 Infection in Children
We showed that 93% of the children with underlying 
chronic medical conditions who were eligible for vaccina-
tion had not been vaccinated. This fi nding highlights a need 
to improve vaccine coverage among this population, for 
which infl uenza vaccination is recommended in Germany 
(39). Children who did not survive received more inten-
sive treatment (mechanical ventilation and catecholamine) 
than those who survived, and nearly all infl uenza A viruses 
tested continue to be antigenically similar to those found 
in the current trivalent vaccine (40); thus, enhanced pre-
vention in children through vaccination, especially among 
those with underlying chronic medical conditions, remains 
a high priority.
Our study is subject to several limitations. Factors such 
as physicians’ awareness, diagnostic testing, and reporting 
behavior, which may have had different infl uences in the 
2 seasons, were not assessed. Only children hospitalized 
in pediatric hospitals were included in the study; however, 
it can be assumed that critically ill children hospitalized 
in general hospitals were transferred to pediatric hospitals 
covered by the ESPED network. In addition, our knowl-
edge of the clinical features of patients was based only on 
information provided in the structured questionnaires. As-
certainment of underlying chronic medical conditions was 
not standardized and, thus, may have differed among treat-
ing physicians.
Conclusions
During the fi rst postpandemic A(H1N1)pdm09 season, 
the situation for children with severe A(H1N1)pdm09 dis-
ease did not differ from that for children with severe dis-
ease during the pandemic. Signs of pulmonary failure or 
suspected myocarditis in such children should alert health 
care providers to immediately initiate maximum care, and 
prevention of nosocomial transmission of infl uenza virus 
should be reinforced, especially in immunosuppressed chil-
dren. The unchanged severity of infl uenza A(H1N1)pdm09 
virus infections in the fi rst postpandemic season (2010–11) 
and the constant high proportion of possibly hospital-ac-
quired infections stress the challenge of preventing severe 
cases in children beyond the pandemic situation.
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